Medically Reviewed by: Dr. Dipak Ladda, M.D.
Expertise: Consultant Pathologist
Last Updated: July 24, 2026
Medical Analysis
Understanding Glucagon: Endocrine Hormone and Metabolic Regulation
Glucagon is a critical peptide hormone secreted by the alpha cells of the pancreatic islands of Langerhans [1, 13]. This hormone plays a foundational role in regulating the metabolism of carbohydrates, fats, and proteins within the human body [14]. By controlling glucose production and secretion by the liver, glucagon ensures that blood sugar levels are maintained, particularly during periods of fasting and hypoglycemia [3, 4]. The relationship between glucagon levels and catabolism is direct, and its actions are fundamentally opposite to those of insulin [12, 14]. Because of this essential regulatory role, glucagon serves as an important diagnostic tool for various metabolic and endocrine disorders [12, 15].
The relationship between insulin, glucagon, and glucose is a complex feedback loop. When blood sugar is high, the pancreas promotes insulin release, which stimulates glucose uptake by tissue cells and triggers the liver to stimulate glycogen formation, ultimately lowering blood sugar [3, 9]. Conversely, when blood sugar is low, the pancreas promotes glucagon release. Glucagon then stimulates glycogen breakdown in the liver, which raises blood sugar levels [3, 4, 14].
Physiological Mechanism of Glucagon Action
When glucagon is released, it triggers several physiological responses:
Glucagon secretion suppresses insulin-sensitive cells’ use of glucose [14].
Glycogen breakdown begins in the liver [3, 14].
It stimulates gluconeogenesis [14].
It promotes fat breakdown [14].
It facilitates protein breakdown [14].
Conversely, it inhibits DNA synthesis, protein synthesis, and the storage of glucose in the form of glycogen in the liver and skeletal muscles [14].
Clinical Indications and Metabolic Assessment
Clinicians monitor glucagon levels based on specific patient symptoms and broader endocrine assessments.
Symptoms and Clinical Indications
Patients presenting with the following symptoms may require assessment of glucagon levels:
High blood sugar [5, 12].
Excessive thirst [5].
Excessive hunger [5].
Diagnostic Assessment Categories
| Category | Indications |
| Endocrine Disorders | Evaluation of growth hormone deficiency, Assessment of adrenal insufficiency [6, 15] |
| Metabolic Assessment | Investigation of hypoglycemia, Assessment of glycogen storage diseases [4, 14] |
| Pituitary Function | Alternative to insulin tolerance test (when contraindicated) [6] |
| Research/Other Uses | Studies of glucose metabolism, Hormonal reserve testing [8, 15] |
| Glucagonoma | Unexplained Hyperglycemia [10, 11] |
For Non-Medicos: Laboratory Procedures and Interpretations
For patients undergoing laboratory testing, precise adherence to collection protocols is essential for accurate results.
Patient Preparation and Sample Collection Protocols
Patients are instructed to stop taking biotin—also known as vitamin B7, B8, vitamin H, or coenzyme R—at least 72 hours prior to the test. A 1 ml blood sample must be collected in an EDTA container. Because frozen plasma is required for accurate analysis, the sample must be transported in a chilled state. Laboratory staff must separate the plasma and transfer the specimen to a plastic transport tube before freezing. Once frozen, the sample remains stable for 7 days.
Reference Ranges and Clinical Variations
The normal range for glucagon is 13–159 pg/ml. However, it is important to note that levels depend heavily on the specific assay used, and clinical labs may vary; therefore, one should always refer to the lab-specific reference [1, 2]. Glucagon levels naturally increase during periods of prolonged fasting and hypoglycemia [4, 7]. Abnormally high levels may indicate the presence of a glucagonoma (a pancreatic tumor), liver disease, or other endocrine disorders [10, 11, 13]. Given these variables, proper sample collection and rapid freezing are considered critical steps for achieving accurate clinical measurements [1, 6].
References:
Unger, R. H., Aguilar-Parada, E., Müller, W. A., & Eisentraut, A. M. (1970). Studies of pancreatic alpha cell function in normal and diabetic subjects. Journal of Clinical Investigation, 49(4), 837–848.
Lefebvre, P. J. (1995). Glucagon and its family. Diabetologia, 38(7), 844–850.
Cherrington, A. D. (1999). Control of glucose uptake and release by the liver in vivo. Diabetes, 48(6), 1198–1214.
Cryer, P. E. (2001). The prevention and correction of hypoglycemia in diabetes. Diabetes, 50(12), 2661–2667.
Raskin, P., & Unger, R. H. (1978). Hyperglucagonemia and its suppression: Importance in the metabolic control of diabetes. New England Journal of Medicine, 299(9), 433–436.
Wensel, T. M., & Unger, R. H. (2012). Glucagon and the alpha cell: A new look at an old regulator. Journal of Clinical Investigation, 122(10), 3398–3400.
Quddusi, S., Vajo, Z., Haluzik, M., & Campbell, P. J. (2003). Alleviation of fasting hyperglycemia in type 2 diabetes by insulin glargine-mediated suppression of hepatic glucose production. Diabetes, 52(1), 21–26.
Knop, F. K., Vilsbøll, T., & Holst, J. J. (2007). Incretin-based therapy of type 2 diabetes mellitus. Journal of Endocrinology, 194(1), 1–16.
Elrick, H., Stimmler, L., Hlad, C. J., & Arai, Y. (1964). Plasma insulin response to oral and intravenous glucose administration. Journal of Clinical Endocrinology & Metabolism, 24(10), 1076–1082.
Marks, V., & Samols, E. (1970). Glucagonoma syndrome. Gut, 11(4), 346–352.
Aspinall, S. L., & Good, C. B. (1995). Management of glucagonoma. Annals of Pharmacotherapy, 29(2), 173–175.
Unger, R. H., & Cherrington, A. D. (2012). Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover. Journal of Clinical Investigation, 122(1), 4–12.
Gromada, J., Chabosseau, P., & Rutter, G. A. (2018). The alpha-cell in diabetes. Frontiers in Endocrinology, 9, 268.
Jiang, G., & Zhang, B. B. (2003). Glucagon and regulation of glucose metabolism. American Journal of Physiology-Endocrinology and Metabolism, 284(4), E671–E678.
Dunning, B. E., & Gerich, J. E. (2007). The role of alpha-cell dysfunction in glucose intolerance. Endocrine Reviews, 28(3), 253–283.
FAQ’s:
What is glucagon hormone?
Glucagon is a peptide hormone secreted by pancreatic alpha cells that regulates blood glucose metabolism.How does glucagon affect glucose?
It raises blood sugar by stimulating glycogen breakdown and gluconeogenesis in the liver during fasting.Does insulin oppose glucagon?
Yes, insulin and glucagon actions are opposite; insulin lowers blood sugar while glucagon increases it.When is glucagon released?
The pancreas releases glucagon when blood sugar levels are low to maintain glucose homeostasis.What symptoms suggest glucagon testing?
Clinical indications include symptoms like high blood sugar, excessive thirst, and excessive hunger.Why stop biotin before testing?
Patients must stop biotin for 72 hours to prevent interference with accurate laboratory test results.How is blood collected?
Collect 1 ml of blood in an EDTA container, then process and freeze the plasma immediately.What is the normal range?
The normal reference range for glucagon in the blood is 13–159 pg/ml.Can high levels indicate tumors?
Yes, high glucagon levels may indicate a glucagonoma, which is a rare type of pancreatic tumor.How long is frozen stable?
Properly collected and frozen plasma samples remain stable for up to 7 days for analysis.
